Vanda Pharmaceuticals, Inc., announced this week that its new antidepressant Tasimelteon failed to beat placebo in trials, and that it has hence ended its program of trials for the drug.
Of further interest: Vanda Drug Fails in Depression Study (Motley Fool)
